ImmuPharma PLC (LSE:IMM), (“ImmuPharma” or the “Company”), the specialist drug discovery and development company, held its AGM earlier today and is pleased to announce that all resolutions were duly passed. A summary of proxy votes is shown in the table attached, click here. Please also refer to the ‘Notice of the 2015 Annual General Meeting’ in…

ImmuPharma PLC (LSE:IMM), (“ImmuPharma” or the “Company”), the specialist drug discovery and development company confirms that the Annual Report and Accounts for the year ended 31 December 2014 will be posted to shareholders today. The Annual Report will be available later today, in electronic form, for download on the Company’s website www.immupharma.co.uk. The Company’s Annual…

ImmuPharma PLC (LSE:IMM), (“ImmuPharma” or the “Company”), the specialist drug discovery and development company, is pleased to announce its preliminary audited results for the year ended 31 December 2014. Key Highlights: LupuzorTM Agreement signed with Simbec-Orion, an international clinical research organisation, to undertake crucial Phase III clinical trial including a commitment to reinvest a significant…

ImmuPharma PLC (LSE:IMM), (“ImmuPharma” or the “Company”), the specialist drug discovery and development company, is pleased to announce the appointment of Dr Stéphane Méry as non-executive director. Dr Stéphane Méry has extensive experience in the Healthcare industry. He is currently CEO of Contronics Ltd, which designs and sells laboratory monitoring equipments, and until recently he…

ImmuPharma PLC (LSE:IMM), (“ImmuPharma” or the “Company”), the specialist drug discovery and development company, provides an update on its lead Cancer programme – IPP-204106. As previously stated, the Phase I/IIa clinical trial with the next generation “polyplexed Nucant” formulation taking place in three European hospitals including the prestigious Institute Jules Bordet in Belgium, has been…

ImmuPharma PLC (AIM: IMM) (“ImmuPharma” or the “Company”), the specialist drug discovery and development company, announces that it has received advance assurance from H M Revenue and Customs that it would qualify for Enterprise Investment Scheme (EIS) status. EIS offers a range of tax reliefs to investors who invest in qualifying companies.  These tax reliefs…

Deal provides powerful validation for Lupuzor™ ImmuPharma PLC (AIM: IMM) (“ImmuPharma”) and Simbec-Orion Group Limited (“Simbec-Orion”) announce that they have today entered into a Collaboration Agreement for the execution of ImmuPharma’s Pivotal Phase III clinical study of Lupuzor™. Lupuzor™ (also known as Rigerimod, IPP-201101 and P140), is ImmuPharma’s lead compound for the treatment of Lupus,…